Tevogen Bio inks related-party facility deal with CD8 for cell therapy production

Tevogen Bio Holdings Inc.

Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.
Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.
Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.
Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.